Pediatric Cancers

Children diagnosed with non-central nervous system cancers at a very young age tend to reach some neurodevelopmental milestones later than healthy children, according to a new study.

The article by Dr. George is of great use to the practicing clinician, not only in the hematology-oncology setting but also in general practice or emergency medicine.

The cure of childhood acute lymphocytic leukemia (ALL) stands at the top of medicine's achievements in the struggle against cancer.

Here we present the case of a 3-year-old girl with generalized lymphadenopathy and fever, in whom the cause of the symptoms was initially thought to be infectious. Ultimately, however, anaplastic large cell lymphoma (ALCL) was diagnosed. Using this case as a backdrop, we discuss the wide range of systemic illnesses that the differential diagnosis of generalized lymphadenopathy encompasses.

Parents and their children need to understand that advancing science does not always go hand-in-hand with a direct benefit to the patients.

Most of the youngest Americans have viewed IPods and video games as essentials for many years. Yet their use to distract kids with cancer from their pain is still in beta testing.

A collaborative project to sequence the neuroblastoma cancer genome could revolutionize diagnosis and treatment.

Dr. Merchant provides a comprehensive overview of intracranial ependymoma in children. As he points out, most of the current information regarding childhood intracranial ependymoma has come from single-institution retrospective reviews. Of the prognostic indicators mentioned in the article, both young age and subtotal resection are widely accepted. Children less than 3 years old have a worse prognosis than older children, possibly because of more aggressive tumor biology, reluctance to give postoperative radiotherapy, or use of lower doses of radiotherapy. Regarding the degree of surgical resection, assessment by postoperative imaging is more important than the neurosurgeon’s perspective on whether a gross total or subtotal resection has been performed.[1,2]

Ependymoma is a rare central nervous system (CNS) tumor in children, and our progress in treating this disease has been hampered by its rarity as well as by a nonuniform approach to treatment among practitioners. Dr. Merchant’s comprehensive review provides a framework for plotting a course of further progress in treating children with ependymoma.

Radiation therapy has long been a mainstay in the treatment of ependymoma. Concerns about the long-term effects of radiation therapy have made many parents and caregivers wary of this treatment modality. However, with the advent of conformal radiation and evidence

VIENNA, Austria-More than two thirds of children who have terminal cancer need opioids or other strong analgesics, most commonly oral morphine. Transdermal fentanyl patches (Duragesic) can replace oral morphine in many of these cases and also offer an alternative for patients who cannot take oral drugs, A. Goldman, MD, Institute of Child Health, London, said at the 9th World Congress on Pain.

Over the past 20 years, dramatic improvements have been made in the treatment of childhood malignancies. Today, most children who have cancer are expected to survive their disease and become healthy, productive members of society. Children with acute lymphoblastic leukemia (ALL) are a good example. Although pediatric ALL was an invariably fatal disorder in the past, children with this cancer now have a 5-year event-free survival rate of more than 70%.

Long-term neurotoxicity associated with central nervous system (CNS) prophylaxis for childhood acute lymphoblastic leukemia (ALL), primarily involving physical growth and cognitive development, is an ongoing

BUFFALO, NY--While most long-term survivors of childhood cancer suffer few psychological scars, up to 30% of fathers and 40% of mothers may exhibit moderate to severe symptoms of post-traumatic stress (PTS)--a disorder commonly associated with war veterans and victims of violent crime.

For all the vast literature concerning survival after treatment for cancer, few articles provide long-term follow-up. At best, most provide 5-year survival statistics, the majority being actuarial, which means that many of the patients included do not even have 5-year follow-up. A few articles give 10-year data and call these long-term. But 5 or even 10 years is not a very long time for a child or young adult hoping for a normal life span, or for clinicians wishing to be able to predict a patient's prognosis after treatment.

The diagnosis and treatment of children with brain tumors has changed radically over the last 50 years. Cross-sectional imaging, CT and MRI, has displaced angiography and pneumoencephalography. These newer imaging modalities have facilitated early diagnosis, preoperative planning, and surgical approach, resulting in an increased likelihood of achieving complete surgical extirpation. The operating microscope has improved the experienced surgeon's ability to discriminate between tumor and normal brain, making radical resection more frequent. Chemotherapy has been introduced into the arsenal of the neuro-oncologist, albeit with only modest success. The one nearly constant treatment modality has been external-beam irradiation.

Outcome is described for 1,034 children who received radiation treatment in the management of a brain tumor at the University of Toronto Institutions from 1958 to 1995. The 5-, 10-, 20-, and 30-year relapse-free (or